Targovax announces encouraging data in mesothelioma study combining ONCOS-102 and standard of care chemotherapy
(WorldNews Norway)

Targovax announces encouraging data in mesothelioma study combining ONCOS-102 and standard of care chemotherapy · Preliminary data show a numerical advantage in Progression Free Survival in ONCOS-102 treated patients · Robust immune activation in the experimental group, with a positive association between immune response and clinical outcome · Combination treatment with ONCOS-102 and chemotherapy is well tolerated · Discussions ongoing with a prospective pharma collaboration partner to move forward with a checkpoint inhibitor combination study Oslo, Norway, 21 January 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target...